Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.
Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.
复制标题
Tau作为阿尔茨海默病认知障碍和神经精神症状的生物标志物。
DOI：
10.1002/hbm.26043
复制
发表时间：
2023-02-01
影响因子：
4.8
通讯作者：
中科院分区：
文献类型：
--
作者：
A/T/N研究框架已被提出用于阿尔茨海默病（AD）的诊断和预后。然而，在AD患者中ATN生物标志物的空间分布及其与认知障碍和神经精神症状的关系需要进一步阐明。我们扫描了83名AD患者和38名认知正常的对照者，他们独立完成了简易精神状态检查和神经精神量表。使用统计参数图以及[18 F]flortaucipir、[18 F]florbetapir和[18 F]FDG正电子发射断层扫描表征Tau、Aβ和代谢减退的空间模式。使用分段线性回归、双样本t检验和支持向量机算法探索tau、Aβ和代谢减退与认知、认知障碍和AD诊断之间的关系。结果表明，tau蛋白沉积区域具有区域特异性，主要发生在AD的下颞叶，与低代谢区域广泛重叠。而Aβ的沉积区域具有独特性，受代谢低下影响的区域分布广泛。与Aβ不同，tau蛋白和低代谢在AD晚期随着认知障碍的增加而单调增加。此外，AD患者的tau蛋白沉积与tau蛋白沉积密切相关，其次是低代谢，但与Aβ无关。最后，低代谢和tau蛋白在区分AD患者和对照组方面的准确性（准确性= 0.88，准确性= 0.85）高于Aβ（准确性= 0.81），并且三者结合的准确性最高（准确性= 0.95）。这些发现表明tau病理学在识别认知障碍和认知障碍方面上级Aβ和葡萄糖代谢。其结果支持tau累积可用作AD临床损害的生物标志物。A/T/N的空间格局不同。AD患者的神经精神症状（NPSs）与认知功能下降和tau蛋白沉积相关。其中，tau蛋白沉积对抑郁、冷漠、异常运动行为和食欲障碍症状有显著影响。
The A/T/N research framework has been proposed for the diagnosis and prognosis of Alzheimer's disease (AD). However, the spatial distribution of ATN biomarkers and their relationship with cognitive impairment and neuropsychiatric symptoms (NPS) need further clarification in patients with AD. We scanned 83 AD patients and 38 cognitively normal controls who independently completed the mini‐mental state examination and Neuropsychiatric Inventory scales. Tau, Aβ, and hypometabolism spatial patterns were characterized using Statistical Parametric Mapping together with [18F]flortaucipir, [18F]florbetapir, and [18F]FDG positron emission tomography. Piecewise linear regression, two‐sample t‐tests, and support vector machine algorithms were used to explore the relationship between tau, Aβ, and hypometabolism and cognition, NPS, and AD diagnosis. The results showed that regions with tau deposition are region‐specific and mainly occurred in inferior temporal lobes in AD, which extensively overlaps with the hypometabolic regions. While the deposition regions of Aβ were unique and the regions affected by hypometabolism were widely distributed. Unlike Aβ, tau and hypometabolism build up monotonically with increasing cognitive impairment in the late stages of AD. In addition, NPS in AD were associated with tau deposition closely, followed by hypometabolism, but not with Aβ. Finally, hypometabolism and tau had higher accuracy in differentiating the AD patients from controls (accuracy = 0.88, accuracy = 0.85) than Aβ (accuracy = 0.81), and the combined three were the highest (accuracy = 0.95). These findings suggest tau pathology is superior over Aβ and glucose metabolism to identify cognitive impairment and NPS. Its results support tau accumulation can be used as a biomarker of clinical impairment in AD. Spatial patterns of A/T/N were different. Neuropsychiatric symptoms (NPS) in AD patients were associated with cognitive decline and tau deposition. Among NPS, tau deposition had a significant impact on depression, apathy, aberrant motor behaviour, and appetit disturbance symptoms.
登录
查看更多内容
影响因子：
7
作者：
de Medeiros K;Robert P;Gauthier S;Stella F;Politis A;Leoutsakos J;Taragano F;Kremer J;Brugnolo A;Porsteinsson AP;Geda YE;Brodaty H;Gazdag G;Cummings J;Lyketsos C
通讯作者：
Lyketsos C
影响因子：
15.1
作者：
Chen Y;Dang M;Zhang Z
通讯作者：
Zhang Z
影响因子：
120.7
作者：
Jansen, Willemijn J.;Ossenkoppele, Rik;Knol, Dirk L.;Tijms, Betty M.;Scheltens, Philip;Verhey, Frans R. J.;Visser, Pieter Jelle
通讯作者：
Visser, Pieter Jelle
影响因子：
14.5
作者：
Knopman, David S.;Lundt, Emily S.;Jack, Clifford R., Jr.
通讯作者：
Jack, Clifford R., Jr.
影响因子：
14.5
作者：
Kim, EJ;Cho, SS;Na, DL
通讯作者：
Na, DL